Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Multiple Sclerosis Excellence Forum

Multiple Sclerosis
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Multiple Sclerosis: What’s on the Horizon for 2021?
Podcasts
Multiple Sclerosis: What’s on the Horizon for 2021?
02/22/2021
In this podcast, Patricia K. Coyle, MD, discusses anticipated developments in the field of multiple sclerosis this year, including clinical trial data, COVID-19 vaccination, wearable devices, and more. A full transcript is provided.
In this podcast, Patricia K. Coyle, MD, discusses anticipated developments in the field of multiple sclerosis this year, including clinical trial data, COVID-19 vaccination, wearable devices, and more. A full transcript is provided.
In this podcast, Patricia K....
02/22/2021
Neurology
Multiple Sclerosis and COVID-19 Vaccination: What We Know So Far
Q&As
Multiple Sclerosis and COVID-19 Vaccination: What We Know So Far
02/17/2021
Farrah Mateen, MD, PhD, from Harvard Medical School and Massachusetts General Hospital in Boston, answers our questions about current recommendations for COVID-19 vaccination among patients with multiple sclerosis, as well as key areas of...
Farrah Mateen, MD, PhD, from Harvard Medical School and Massachusetts General Hospital in Boston, answers our questions about current recommendations for COVID-19 vaccination among patients with multiple sclerosis, as well as key areas of...
Farrah Mateen, MD, PhD, from...
02/17/2021
Neurology
Patricia K. Coyle, MD: The Latest on MOG-Mediated Disease in Multiple Sclerosis
Podcasts
Patricia K. Coyle, MD: The Latest on MOG-Mediated Disease in Multiple Sclerosis
02/08/2021
In this podcast, Dr Coyle discusses the "final word" on myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting. A full transcript is provided.
In this podcast, Dr Coyle discusses the "final word" on myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting. A full transcript is provided.
In this podcast, Dr Coyle...
02/08/2021
Neurology
Decoding the Multiple Sclerosis Prodrome
Commentary
Decoding the Multiple Sclerosis Prodrome
01/25/2021
Prodromes are well documented for neurodegenerative disorders such as Parkinson disease and Alzheimer disease, and there are increasing data for a multiple sclerosis (MS) prodrome, writes Patricia K. Coyle, MD, from Stony Brook University. In...
Prodromes are well documented for neurodegenerative disorders such as Parkinson disease and Alzheimer disease, and there are increasing data for a multiple sclerosis (MS) prodrome, writes Patricia K. Coyle, MD, from Stony Brook University. In...
Prodromes are well documented...
01/25/2021
Neurology
Patricia K. Coyle, MD: Emerging Data on Remyelination in Multiple Sclerosis
Podcasts
Patricia K. Coyle, MD: Emerging Data on Remyelination in Multiple Sclerosis
12/22/2020
In this podcast, Dr Coyle discusses the "final word" on strategies to promote remyelination in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Coyle discusses the "final word" on strategies to promote remyelination in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Coyle...
12/22/2020
Neurology
Low Infection Risk With Ozanimod: New Long-Term Safety Data at a Glance
Videos
Low Infection Risk With Ozanimod: New Long-Term Safety Data at a Glance
12/21/2020
In this video, Amit Bar-Or, MD, FRCPC, gives an overview of encouraging findings regarding the long-term safety of ozanimod for relapsing forms of multiple sclerosis.
In this video, Amit Bar-Or, MD, FRCPC, gives an overview of encouraging findings regarding the long-term safety of ozanimod for relapsing forms of multiple sclerosis.
In this video, Amit Bar-Or, MD,...
12/21/2020
Neurology
Exploring the Transformation of Diffusely Abnormal White Matter Regions into Focal White Matter Lesions in SPMS
Q&As
Exploring the Transformation of Diffusely Abnormal White Matter Regions into Focal White Matter Lesions in SPMS
12/14/2020
Mahsa Dadar, PhD, answers our questions about her new study that suggested diffusely abnormal white matter regions in the brain evolve into focal white matter lesions over time in secondary progressive multiple sclerosis, which in turn may be...
Mahsa Dadar, PhD, answers our questions about her new study that suggested diffusely abnormal white matter regions in the brain evolve into focal white matter lesions over time in secondary progressive multiple sclerosis, which in turn may be...
Mahsa Dadar, PhD, answers our...
12/14/2020
Neurology
Q&A: Shiv Saidha, MBBCh, Discusses the Impact of BMI on Retinal Atrophy in MS
Q&As
Q&A: Shiv Saidha, MBBCh, Discusses the Impact of BMI on Retinal Atrophy in MS
12/07/2020
Shiv Saidha, MBBCh, answered our questions about his study, which suggests that elevated body mass index may be associated with accelerated ganglion cell + inner plexiform layer atrophy in the absence of overt metabolic comorbidities among...
Shiv Saidha, MBBCh, answered our questions about his study, which suggests that elevated body mass index may be associated with accelerated ganglion cell + inner plexiform layer atrophy in the absence of overt metabolic comorbidities among...
Shiv Saidha, MBBCh, answered our...
12/07/2020
Neurology
Review of Long-Term Data on Ozanimod's Low Infection Risk, Favorable Safety Profile
Videos
Review of Long-Term Data on Ozanimod's Low Infection Risk, Favorable Safety Profile
12/03/2020
In this video, Amit Bar-Or, MD, FRCPC, discusses new long-term data that show a favorable safety profile over time with the use of ozanimod among patients with relapsing forms of multiple sclerosis.
In this video, Amit Bar-Or, MD, FRCPC, discusses new long-term data that show a favorable safety profile over time with the use of ozanimod among patients with relapsing forms of multiple sclerosis.
In this video, Amit Bar-Or, MD,...
12/03/2020
Neurology
Patricia K. Coyle, MD: Updates on Neuromyelitis Optica Spectrum Disorder in Multiple Sclerosis
Podcasts
Patricia K. Coyle, MD: Updates on Neuromyelitis Optica Spectrum Disorder in Multiple Sclerosis
11/24/2020
In this podcast, Dr Coyle discusses the "final word" on neuromyelitis optica spectrum disorder in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Coyle discusses the "final word" on neuromyelitis optica spectrum disorder in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Coyle...
11/24/2020
Neurology

Advertisement

Advertisement

News

neurologist and patient
New Study Brief
Study Emphasizes Importance of Appropriate Application of McDonald Criteria in PPMS Diagnoses
09/15/2023
A comprehensive approach to primary progressive multiple sclerosis (PPMS) diagnosis that includes correct application of the McDonald criteria in real-world settings can improve diagnostic accuracy.
A comprehensive approach to primary progressive multiple sclerosis (PPMS) diagnosis that includes correct application of the McDonald criteria in real-world settings can improve diagnostic accuracy.
A comprehensive approach to...
09/15/2023
Neurology
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement